Fast assembly of bio-inspired nanocomposite films

This paper presents a spin-coating layer-by-layer assembly process to prepare multilayered polyelectrolyte-clay nanocomposites. This method allows for the fast production of films with controlled layered structure. The preparation of a 100-bilayer film with a thickness of about 330 nm needs less than 1 h, which is 20 times faster than conventional dip-coating processes maintaining the same hardness and modulus values. For validation of this technique, nanocomposite films with thicknesses up to 0.5 μm have been created with the common dip self-assembly and with the spin coating layer-by-layer assembly technique from a poly(diallyldimethylammonium)chloride (PDDA) solution and a suspension of a smectite clay mineral (Laponite). Geometrical characteristics (thickness, roughness, and texture) as well as mechanical characteristics (hardness and modulus) of the clay-polyelectrolyte films have been studied. The spin-coated nanocomposite films exhibit clearly improved mechanical properties (hardness 0.4 GPa, elastic modulus 7 GPa) compared to the "pure” polymer film, namely a sixfold increase in hardness and a 17-fold increase in Young's modulu

Fast assembly of bio-inspired nanocomposite films

ISSN:0884-2914ISSN:2044-532

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA) : Rationale, Design, and Baseline Data

Altres ajuts: F. Hoffmann-La Roche Ltd.Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. Methods: The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations. Results: Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve). Conclusions: The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD. Trial Registration: NCT03100149